- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05881369
Examining Clinical Research Participation for Substance Abuse Disorder Patient
Exploring the Clinical Trial Journey of Patients in Substance Abuse Disorder Clinical Trials
Clinical study participation percentages haven't always been fully representative of a given demographic.
The goal is to find out which aspects of a clinical trial may make it more difficult for patients to take part or see it through.
The data will be evaluated through different demographic lenses and identify trends that could help improve the experience of future substance abuse disorder patients during clinical trials.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Michael B Gill
- Phone Number: 415-900-4227
- Email: bask@withpower.com
Study Locations
-
-
California
-
San Francisco, California, United States, 94107
- Power Life Sciences
-
Contact:
- Michael B Gill
- Phone Number: 415-900-4227
- Email: https://www.withpower.com/contact-us@withpower.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed.
- Participant has a diagnosis of substance abuse disorder.
- Willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study.
Exclusion Criteria:
- Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent.
- Pregnant or lactating woman
- Known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug(s) administration or interfere with the interpretation of safety results
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of patients who decide to enroll in a substance abuse disorder clinical study.
Time Frame: 3 months
|
3 months
|
Number of substance abuse disorder patients who remain in clinical trial until completion.
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Michael B Gill, Power Life Sciences Inc.
Publications and helpful links
General Publications
- Jaguga F, Kwobah E. A review of the public sector substance use disorder treatment and prevention systems in Kenya. Subst Abuse Treat Prev Policy. 2020 Jul 20;15(1):47. doi: 10.1186/s13011-020-00291-5.
- Kock P, Froelich K, Walter M, Lang U, Dursteler KM. A systematic literature review of clinical trials and therapeutic applications of ibogaine. J Subst Abuse Treat. 2022 Jul;138:108717. doi: 10.1016/j.jsat.2021.108717. Epub 2021 Dec 30.
- Tull MT, Gratz KL. The impact of borderline personality disorder on residential substance abuse treatment dropout among men. Drug Alcohol Depend. 2012 Feb 1;121(1-2):97-102. doi: 10.1016/j.drugalcdep.2011.08.014. Epub 2011 Sep 9.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 91257336
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Substance Abuse Disorder
-
University of California, IrvineUS Department of Veterans AffairsWithdrawn
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)CompletedSubstance Abuse DisorderUnited States
-
Kaiser PermanenteNational Institute on Drug Abuse (NIDA)Active, not recruitingOpioid Use Disorder | Substance Use Disorders | Substance Abuse | Opioid Abuse | Drug Abuse | Drug Use Disorders | Cannabis Abuse | Cannabis-Related Disorder
-
West Virginia UniversityRecruitingSubstance Abuse DisorderUnited States
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)CompletedSubstance Abuse DisorderUnited States
-
SangathHarvard Medical School (HMS and HSDM); London School of Hygiene and Tropical...CompletedMental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse)India
-
Tokyo UniversityCompletedMental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse)
-
Arizona State UniversityNational Institute on Drug Abuse (NIDA)CompletedMental Health Disorder | Drug Abuse | DivorceUnited States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
Institut Català d'OncologiaHospital Clinic of Barcelona; Fundació Institut de Recerca de l'Hospital de... and other collaboratorsRecruitingSmoking Cessation | Tobacco Use | Mental Health Disorder | Cannabis Use | Alcohol Abuse | Substance Abuse DrugSpain